A 57-year-old, previously healthy, postmenopausal, woman underwent gynecological examination in July 2013 due to suspicious findings in the right mammary. Physical examination with palpation revealed a vague finding in the area of right mammary, about two finger breadths right caudally of the right mammary. The finding was mammographically and mammasonographically suspicious and an MRI of the mammaries was arranged. Laboratory tests produced no evidence of inflammation. The MRT of the mammaries on 12.7.2013 showed an architectural distortion 12 cm in size at the lower outer-side of the right mammary about 20 mm from the curtis and 22 cm along the inframammary crease. The lesion was radially configured and absorbed the contrast agent strongly at the center (MRM-BI-RADS 5; compare image left, MRI of 12.7.2013), the left mammary was normal. The conclusion was that there was suspicion of unifocal breast cancer. The patient rejected donation of a tissue sample. The patient also requested that no further medical diagnosis/therapy should take place. Thereafter, on 29.09.2013, the patient started therapy consisting of anthropofonetics, counselling and a change of diet.
A 62-year-old, previously healthy woman was admitted to hospital on 28.3.2012 with an ileus and surgical abdomen requiring emergency operation (Hartmann's procedure for a discontinuity resection). Intraoperatively, a sigma carcinoma with stenosis was found to be the cause of the ileus. The tumor formula was as follows: pT4a N2b (13/24) L1 V1, G2, R0 M0. After convalescence, adjuvant chemotherapy was performed from April to September 2012 following the Xelox scheme.
Continuity was restored on 17.10.2012 without complications.
During follow-up examinations, ovarian cystic lesions were found on 28.3.2014, first sonographically and then with a CT scan of both ovaries. Differential diagnosis showed cystadenocarcinomas of the ovary. The patient underwent an adnexectomy on both sides on 6/26/2014. Histologically, three metastases of the known sigma carcinoma (CK20+; CK7-) were discovered. The metastases on the right ovary were R0 resected, in the area of the left ovary only one R1 resection was achieved. The biopsy of the Douglas area also showed cells of the colon carcinoma histologically.
Postoperatively, additive chemotherapy was performed with FOLFIRI and with bevacizumab (KRAS gene mutations in exon 2). Treatment was administered from June to November 2014 whereby treatment tolerability was good, there was a complication when a port-associated thrombosis occurred, which was treated with 7.5mg Arixtra. A CT thoracic to pelvic scan in November 2014 was normal with regard to distant metastases, so the therapy could be terminated and further follow-up was initiated. By July 2015, systemic progress of the disease was demonstrated with multiple metastases on both lungs, as well as paraaortal and parailiac lymph nodes, a few of which were measured with a size up to 3cm.
The patient was then treated with chemotherapy with 5-fluoruacil, folinic acid and bevacizumab beginning on 20.7.2015 at 2 week intervals initially, later 3-4 week intervals. The treatment is currently being administered every 3-4 weeks and is tolerated excellently. The patient does not complain of any side effects. Since July 2015, that is since the beginning of this chemotherapy course, the patient has also been given treatment with Iscador M, 3x / week and anthropofonetics and therapeutic singing 2x / week. The anthropophonic treatment also includes physical exercises that allow a patient to participate actively and thus help them to help themselves in their healing process.
In summary, the patient was diagnosed with an aggressive, twice-recurrent sigma carcinoma. With a chemotherapy course that was less intensive and at longer intervals, and anthroposophic therapy, which began at the second relapse, the patient's illness has been stable for the last 20 months and she feels physically and mentally well.